CA19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC).

被引：0
|
作者：
Chiorean, E. Gabriela
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Infante, Jeffrey R.
Bathini, Venu Gopal
Wood, Tina Evans
Mainwaring, Paul N.
Muldoon, Robert T.
Clingan, Philip R.
Kunzmann, Volker
Ramanathan, Ramesh K.
Tabernero, Josep
Goldstein, David
Ko, Amy
Lu, Brian
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Florida Canc Specialists, Englewood, FL USA
[4] Arena Oncol Associates, Lake Success, NY USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
[6] Tennessee Oncol, Nashville, TN USA
[7] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA
[8] UAB Comprehens Canc Ctr, Birmingham, AL USA
[9] Mater Private Ctr Haematol & Oncol, South Brisbane, Australia
[10] Genesis Canc Ctr, Hot Springs, AR USA
[11] Southern Med Day Care Ctr, Wollongong, NSW, Australia
[12] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[13] Vall dHebron Univ Hosp, Barcelona, Spain
[14] Prince Wales Hosp, Sydney, NSW, Australia
[15] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4058
引用
收藏
页数：1
相关论文
共 50 条
  • [41] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
    Tempero, M. A.
    Cardin, D.
    Biankin, A.
    Goldstein, D.
    Moore, M.
    O'Reilly, E. M.
    Philip, P.
    Riess, H.
    Macarulla, T.
    Yung, L.
    Wei, X.
    Lu, B.
    PANCREAS, 2014, 43 (08) : 1416 - 1416
  • [42] Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase II trial
    Kamata, Ken
    Imai, Hajime
    Matsumoto, Hisakazu
    Yamashita, Yukitaka
    Kato, Takao
    Nishi, Katsuhisa
    Omoto, Shunsuke
    Minaga, Kosuke
    Yamao, Kentaro
    Hyodo, Tomoko
    Im, Sung-Woon
    Hara, Akane
    Yoshikawa, Tomoe
    Ishikawa, Rei
    Okamoto, Ayana
    Yamazaki, Tomohiro
    Nakai, Atsushi
    Ueshima, Kazuomi
    Chiba, Yasutaka
    Takenaka, Mamoru
    Watanabe, Tomohiro
    Kitano, Masayuki
    Kudo, Masatoshi
    JGH OPEN, 2023, 7 (09): : 659 - 666
  • [43] NAB-PACLITAXEL PLUS GEMCITABINE VS GEMCITABINE ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER: INFLUENCE OF PRIMARY PANCREATIC TUMOR LOCATION ON EFFICACY AND TREATMENT EXPOSURE IN THE MPACT PHASE III TRIAL
    Jose, Lopez-Martin
    Wee, Ma Wen
    Christos, Karapetis
    Peter, Balcke
    Hagan, Kennecke
    Michael, Stahl
    Michele, Milella
    Francis, Nugent
    Diane, Prager
    Brian, Lu
    Stefano, Ferrara
    Darryl, Penenberg
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2014, 25 : 28 - 28
  • [44] Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival
    Tempero, M.
    O'Reilly, E.
    Van Cutsem, E.
    Berlin, J.
    Philip, P.
    Goldstein, D.
    Tabernero, J.
    Borad, M.
    Bachet, J.
    Parner, V.
    Tebbutt, N.
    Chua, Y.
    Corrie, P.
    Harris, M.
    Taieb, J.
    Burge, M.
    Kunzmann, V.
    Zhang, G.
    McGovern, D.
    Marks, H.
    Biankin, A.
    Reni, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S226 - S226
  • [45] Gemcitabine (G) plus nab-paclitaxel (nab-P) versus G in patients (pts) with advanced pancreatic cancer (PDAC) after FOLFIRINOX: A single center, retrospective review.
    Chan, Edmond Mankee
    Hong, Theodore S.
    Clark, Jeffrey William
    Blaszkowsky, Lawrence Scott
    Allen, Jill N.
    Zhu, Andrew
    Goyal, Lipika
    Murphy, Janet E.
    Kwak, Eunice L.
    Wo, Jennifer Y.
    Ryan, David P.
    Faris, Jason Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [46] Erratum to: nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial
    Mustapha Tehfe
    Scot Dowden
    Hagen Kennecke
    Robert El-Maraghi
    Bernard Lesperance
    Felix Couture
    Richard Letourneau
    Helen Liu
    Alfredo Romano
    Advances in Therapy, 2017, 34 : 277 - 279
  • [47] Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Moore, Malcolm J.
    Teixeira, Luis
    Siena, Salvatore
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [48] nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
    Goldstein, David
    El-Maraghi, Robert Hassan
    Hammel, Pascal
    Heinemann, Volker
    Kunzmann, Volker
    Sastre, Javier
    Scheithauer, Werner
    Siena, Salvatore
    Tabernero, Josep
    Teixeira, Luis
    Tortora, Giampaolo
    Van Laethem, Jean-Luc
    Young, Rosemary
    Penenberg, Darryl Neil
    Lu, Brian
    Romano, Alfredo
    Von Hoff, Daniel D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02):
  • [49] APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).
    Tempero, Margaret A.
    Cardin, Dana Backlund
    Biankin, Andrew
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen Mary
    Philip, Agop Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Wei, Xinyu
    Lu, Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (PI) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial
    Ko, Andrew H.
    Murphy, Patrick Brian
    Peyton, James D.
    Shipley, Dianna
    Al-Hazzouri, Ahmed
    Rodriguez, Francisco Antonio
    Womack, Mark Sanders
    Xiong, Henry Q.
    Waterhouse, David Michael
    Tempero, Margaret A.
    Guo, Shuangli
    Lane, Cassie Michelle
    Earwood, Christopher
    DeBusk, Laura M.
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345